14Dec/13

Roche, Prothena enter pact to co-develop & market antibodies for Parkinson's … – pharmabiz.com


Economic Times

Roche, Prothena enter pact to co-develop & market antibodies for Parkinson’s …
pharmabiz.com
Roche and clinical stage biotechnology company, Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal antibody for the treatment of …
Roche, Prothena to develop new antibodies for Parkinson’s disease treatmentPharmaceutical Business Review
Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing
Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co …4-traders (press release)
Zacks.com –PMLiVE
all 41 news articles »